Kansal AR - Search Results

1

Patient Preferences for Multi-Cancer Early Detection (MCED) Screening Tests.

Gelhorn H, Ross MM, Kansal AR, Fung ET, Seiden MV, Krucien N, Chung KC. Gelhorn H, et al. Among authors: kansal ar. Patient. 2023 Jan;16(1):43-56. doi: 10.1007/s40271-022-00589-5. Epub 2022 Jul 18. Patient. 2023. PMID: 35844011 Free PMC article.

2

Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK.

Hackshaw A, Cohen SS, Reichert H, Kansal AR, Chung KC, Ofman JJ. Hackshaw A, et al. Among authors: kansal ar. Br J Cancer. 2021 Nov;125(10):1432-1442. doi: 10.1038/s41416-021-01498-4. Epub 2021 Aug 23. Br J Cancer. 2021. PMID: 34426664 Free PMC article.

3

Cost of cancer management by stage at diagnosis among Medicare beneficiaries.

Reddy SR, Broder MS, Chang E, Paydar C, Chung KC, Kansal AR. Reddy SR, et al. Among authors: kansal ar. Curr Med Res Opin. 2022 Aug;38(8):1285-1294. doi: 10.1080/03007995.2022.2047536. Epub 2022 Apr 20. Curr Med Res Opin. 2022. PMID: 35285354

4

Health state utility values by cancer stage: a systematic literature review.

Pourrahmat MM, Kim A, Kansal AR, Hux M, Pushkarna D, Fazeli MS, Chung KC. Pourrahmat MM, et al. Among authors: kansal ar. Eur J Health Econ. 2021 Nov;22(8):1275-1288. doi: 10.1007/s10198-021-01335-8. Epub 2021 Jun 14. Eur J Health Econ. 2021. PMID: 34125315 Free PMC article.

5

The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA.

Tafazzoli A, Ramsey SD, Shaul A, Chavan A, Ye W, Kansal AR, Ofman J, Fendrick AM. Tafazzoli A, et al. Among authors: kansal ar. Pharmacoeconomics. 2022 Nov;40(11):1107-1117. doi: 10.1007/s40273-022-01181-3. Epub 2022 Aug 30. Pharmacoeconomics. 2022. PMID: 36038710 Free PMC article.

6

Modeling hard clinical end-point data in economic analyses.

Kansal AR, Zheng Y, Palencia R, Ruffolo A, Hass B, Sorensen SV. Kansal AR, et al. J Med Econ. 2013 Nov;16(11):1327-43. doi: 10.3111/13696998.2013.838960. Epub 2013 Sep 24. J Med Econ. 2013. PMID: 24032651 Free article. Review.

7

Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries.

Peng S, Deger KA, Ustyugova A, Gandhi P, Qiao N, Wang C, Kansal AR. Peng S, et al. Among authors: kansal ar. Curr Med Res Opin. 2018 Jan;34(1):55-63. doi: 10.1080/03007995.2017.1375470. Epub 2017 Sep 26. Curr Med Res Opin. 2018. PMID: 28862479

8

Cost-effectiveness of a FISH assay for the diagnosis of melanoma in the USA.

Kansal AR, Shaul AJ, Stern S, Busam K, Doucet CA, Chalfin DB. Kansal AR, et al. Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):371-80. doi: 10.1586/erp.13.22. Epub 2013 May 15. Expert Rev Pharmacoecon Outcomes Res. 2013. PMID: 23672374

9

Cost-Effectiveness of Ivabradine for Heart Failure in the United States.

Kansal AR, Cowie MR, Kielhorn A, Krotneva S, Tafazzoli A, Zheng Y, Yurgin N. Kansal AR, et al. J Am Heart Assoc. 2016 May 6;5(5):e003221. doi: 10.1161/JAHA.116.003221. J Am Heart Assoc. 2016. PMID: 27153871 Free PMC article.

10

Comparison of a Markov Cohort Model and a Discrete-Event Simulation for Economic Analyses of Treatments for Multiple Sclerosis.

Kansal A, Tafazzoli A, Leipold R, Sarda S. Kansal A, et al. Value Health. 2014 Nov;17(7):A398. doi: 10.1016/j.jval.2014.08.901. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200939 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

49 results

Search Page